Search

Advanced therapy medicinal products (ATMPs), such as somatic cell-therapy medicinal products or tissue-engineered products for human use, offer new and potentially curative opportunities to treat yet untreatable diseases or disorders. For cell-therapy medicinal products (CBMPs), multiple stability and quality challenges exist and relate to the cellular composition and unstable nature of these parenteral preparations. It is the aim of this review to discuss open questions and problems associated with the development, manufacturing and testing of CBMPs from a pharmaceutical drug product perspective. This includes safety, storage and handling, particulates, the choice of container closure systems and integrity. Analytical methods commonly used to evaluate the quality of the final CBMP to ensure patient's safety will be discussed. Particulate contamination in final products deserve special attention since CBMPs cannot be sterile filtered. Visible and sub-visible particles may represent environmental contaminations or may form during storage. They may be introduced from processing materials such as single use product contact materials, ancillary materials, or any components such as primary packaging used for the final product. Currently available analytical methods for detecting particulates may not be easily applicable to CBMPs due to their inherent particulate nature and appearance.

RNA interference (RNAi) represents a promising new approach to the inhibition of gene expression in vitro and in vivo, and has therapeutic potential for human diseases. Efficient delivery of small interfering RNA (siRNA) or small hairpin RNA (shRNA) is a critical concern in RNAi studies. Here we report the development of a new polymeric gene carrier for cancer cell-targeting, designed to enhance the intracellular delivery of shRNA and reduce cytotoxicity. Folate-chitosan-graft-polyethylenimine (FC-g-PEI) copolymer was prepared by an imine reaction between periodate-oxidized folate-chitosan (FC) and low molecular weight polyethylenimine (PEI). FC-g-PEI copolymer was investigated as a potential cancer cell-targeting gene carrier. The composition of FC-g-PEI was characterized using (1)H nuclear magnetic resonance ((1)H NMR), and particle size and zeta potential of FC-g-PEI/shRNA complexes were measured using dynamic light scattering (DLS). FC-g-PEI showed good shRNA condensation ability and high protection of shRNA from nuclease attack. It also exhibited lower cytotoxicity compared to PEI 25K control, and showed good cancer cell-targeting ability. Furthermore, aerosol delivery of FC-g-PEI/Akt1 shRNA complexes suppressed lung tumorigenesis in a urethane-induced lung cancer model mouse through the Akt signaling pathway. Together, these results suggest that FC-g-PEI may be useful for shRNA-based gene therapy.

Baculovirus, containing an appropriate eukaryotic promoter, is considered an attractive approach for an efficient and safe gene delivery vehicle. However, the drawbacks of baculovirus, such as the lack of specificity and the inactivation of baculovirus by the complement system in human serum, negatively affect efficient gene delivery. Therefore, a hybrid system utilizing the positive aspects of both viral and non-viral vector systems would be useful to overcome the obstacles of either system alone. In this study, we constructed a hybrid system composed of baculovirus (B) and galactosylated polyethylenimine (GP)/DNA complexes through electrostatic interaction. The resulting GP/B hybrid had suitable physicochemical properties and low cytotoxicity for use in gene therapy. Furthermore, the GP/B significantly enhanced transduction efficiency and showed good cell-specificity compared to either viral or non-viral vector systems. These results suggest that the GP/B hybrid system can be used in gene therapy to enhance transduction efficiency and hepatocyte specificity.

Efforts directed in ameliorating silencing studies with shRNA, siRNA and ssiRNA (siRNA with sticky overhangs) are faltered mainly due to the lack of efficient carrier system. In the present study, we developed reductable polyspermine (RPS) carrier composed of multiple spermine units with disulfide linkages for gene expression and silencing studies. In gene expression studies, EGFP expression was found to be almost 4 folds higher and 20 folds safer with RPS carrier than with PEI25K. Moreover, on systemic administration, RPS exhibited significantly high EGFP expression in mice lungs. Similarly in gene silencing studies, EGFP silencing achieved was nearly 1.5 times superior with RPS carrier than PEI25K. Also, RPS delivered Akt1 shRNA (shAkt), siRNA (siAkt) and ssiRNA (ssiAkt) efficiently silenced oncoprotein Akt1 and thereby decreased A549 cell survival. The degrees of cell survival, proliferation and metastasis were differed with the nature of siRNA treatment. Further study at different time intervals revealed that ssiAkt treatment, although superior to sh/siAkt, was highly transient while, shAkt treatment was uniform and prolong. These finding demonstrate the potential use of RPS carrier in gene expression and silencing studies, and significance of the nature of siRNA employed in cancer study.

Efficient delivery of small interfering RNA (siRNA) or small hairpin RNA (shRNA) is a critical concern in RNA interference (RNAi) studies. In the present study, we evaluated biodegradable poly(beta-amino ester) (PAE) carrier composed of low molecular weight polyethylenimine and poly(ethylene glycol) for si/shRNA delivery in lung cancer cells. PAE carrier successfully delivered EGFP (enhanced green fluorescence protein) siRNA (siGFP) and silenced EGFP expression. The silencing achieved with PAE carrier was found to be nearly 1.5 times superior and safer than standard PEI25K. Also, our PAE carrier exhibited superior Akt1 shRNA delivery (shAkt) and thereby silenced oncoprotein Akt1 efficiently. PAE-shAkt mediated Akt1 knock-down hindered cancer cell growth in Akt1 specific manner. Superior shAkt delivery and low cytotoxicity of PAE carrier promoted Akt1 knock-down specific apoptosis, while low delivery efficiency and high cytotoxicity of PEI25K carrier mainly exhibited undesirable necrosis. Moreover, basic cancer properties like cell proliferation, malignancy and metastasis were reduced more efficiently using PAE-shAkt system. These findings demonstrated the potential of PAE as an alternative to PEI25K in si/shRNA-based RNAi studies.

Currently, the success of gene therapy is mainly limited due to the lack of effective vector systems. Although viral vectors are highly efficient in transfecting cells, undesirable complications limit their therapeutic applications. Chitosan has been investigated as a non-viral vector offering several advantages, such as biocompatibility, biodegradability and low toxicity with high cationic potential. However, the low transfection efficiency and low cell specificity of chitosan as a DNA carrier need to be overcome before undertaking clinical trials. The objective of this review is to summarize the use of chitosan and chitosan derivatives in gene therapy, and particularly the role of several factors for the enhancement of transfection efficiency and cell specificity in vitro, such as the degree of deacetylation and molecular weight of chitosan, pH, serum, charge ratio of chitosan to DNA and cell type on transfection efficiency, chemical modification. The administration of the chitosan derivative formulations in vivo is also included, and, the role of chitosan as a carrier of controlled release of DNA and small interfering RNA is described.